ReferencesRajput, AH.Epidemiology of Parkinson's disease. Can J Neurol Sci 1984; 11(1 Suppl): 156–9.
Rajput, AH, Stern, W, Laverty, WH.Chronic low-dose levodopa therapy in Parkinson's disease: an argument for delaying levodopa therapy. Neurology 1984; 34: 991–6.
Tanner, CM.Epidemiology of Parkinson's disease. Neurologic Clin 1992; 10: 317–27.
Lees, AJ, Hardy, J, Revesz, T.Parkinson's disease. Lancet 2009; 373(9680): 2055–66.
Forno, LS.Pathology of Parkinson's Disease. London: Butterworths; 1982.
Hornykiewicz, O, Kish, SJ.Biochemical pathophysiology of Parkinson's disease. Adv Neurol 1987; 45: 19–34.
Montastruc, JL, Senard, JM, Rascol, O, Rascol, A.Autonomic nervous system dysfunction and adrenoceptor regulation in Parkinson's disease. Clinical and pharmacological consequences. Lab Pharmacol Med Clin 1996; 69: 377–81.
Pfeiffer, RF.Gastrointestinal, urological, and sexual dysfunction in Parkinson's disease. Mov Disord 2010; 25 (Suppl 1): S94–7.
Oka, T, Yamamoto, H, Ohashi, N et al. Association between epicardial adipose tissue volume and characteristics of non-calcified plaques assessed by coronary computed tomographic angiography. Int J Cardiol 2012; 161: 45–9.
Barr, A, ed. The Shy–Drager syndrome. In Handbook of Clinical Neurology. New York, NY: Elsevier-North Holland; 1979.
Esper, CD, Factor, SA.Current and future treatments in multiple system atrophy. Curr Treat Options Neurol 2007; 9: 210–23.
Mayeux, RY, Stern, Y, Rosenstein, R et al. An estimate of the prevalence of dementia in idiopathic Parkinson's disease. Arch Neurol 1988; 45: 260–2.
Mayeux, R, Stern, Y, Rosen, J, Leventhal, J.Depression, intellectual impairment, and Parkinson disease. Neurology 1981; 31: 645–50.
Cummings, JL.Managing psychosis in patients with Parkinson's disease. N Engl J Med 1999; 340: 801–3.
Dewey, RB, O'Suilleabhain, PE.Treatment of drug-induced psychosis with quetiapine and clozapine in Parkinson's disease. Neurology 2000; 55: 1753–4.
Friedman, JH, Factor, SA.Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 2000; 15: 201–11.
Paulson, GD, Tafrate, RH.Some “minor” aspects of parkinsonism, especially pulmonary function. Neurology 1970; 20: 14–17.
Mier, M.Mechanisms leading to hypoventilation in extrapyramidal disorders, with special reference to Parkinson's disease. J Am Geriatr Soc 1976; 15: 230–8.
Vincken, WG, Gauthier, SG, Dollfuss, RE et al. Involvement of upper-airway muscles in extrapyramidal disorders. A cause of airflow limitation. N Engl J Med 1984; 311: 438–42.
Irwin, RP, Nutt, JG, Woodward, WR, Gancher, ST.Pharmacodynamics of the hypotensive effect of levodopa in parkinsonian patients. Clin Neuropharmacol 1992; 15: 365–74.
Pfeiffer, RF.Gastrointestinal dysfunction in Parkinson's disease. Parkinsonism Relat Disord 2011; 17: 10–15.
Steele, JC.Progressive supranuclear palsy. Brain 1972; 95: 693–704.
Esper, CD, Weiner, WJ, Factor, SA.Progressive supranuclear palsy. Rev Neurol Dis 2007; 4: 209–16.
Folstein, MS, Folstein, SE, McHugh, PR.“Mini-mental state”. A practical method for grading the state of patients for the clinician. J Psychiatr Res 1975; 12: 189–98.
Brod, TM.Fluoxetine and extrapyramidal side effects. Am J Psychiatry 1989; 146: 1352–3.
Steur, EN.Increase of Parkinson disability after fluoxetine medication. Neurology 1993; 43: 211–13.
Sun-Edelstein, C, Tepper, SJ, Shapiro, RE.Drug-induced serotonin syndrome: a review. Expert Opin Drug Saf 2008; 7: 587–96.
Fernandes, C, Reddy, P, Kessel, B.Rasagiline-induced serotonin syndrome. Mov Disord 2011; 26: 766–7.
Narayan, V, Haddad, PM.Antidepressant discontinuation manic states: a critical review of the literature and suggested diagnostic criteria. J Psychopharmacol 2011; 25: 306–13.
Hyman, SA, Rogers, WD, Smith, DW et al. Perioperative management for transplant of autologous adrenal medulla to the brain for parkinsonism. Anesthesiology 1988; 69: 618–22.
Lipowski, ZJ.Delirium in the elderly patient. N Engl J Med 1989; 320: 578–82.
Berry, P, Ward-Smith, PA.Adrenal medullary transplant as a treatment for Parkinson's disease: perioperative considerations. J Neurosci Nurs 1988; 20: 356–61.
Delgado, J, Billo, JM.Care of the patient with Parkinson's disease: surgical and nursing interventions. J Neurosci Nurs 1988; 20: 142–50.
Guze, BH, Baxer, LR. Neuroleptic malignant syndrome. N Engl J Med 1985; 313: 163.
Kaufman, CA.Neuroleptic malignant syndrome. In Meltzer, H, ed. Psychopharmacology: The Third Generation of Progress. New York, NY: Raven Press; 1987.
Frankel, JP, Lees, AJ, Kempster, PA, Stern, GM.Subcutaneous apomorphine in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 1990; 53: 96–101.
Broussolle, E, Marion, MH, Pollak, P.Continuous subcutaneous apomorphine as replacement for levodopa in severe parkinsonian patients after surgery. Lancet 1992; 340(8823): 859–60.
Mitchelson, F.Pharmacological agents affecting emesis. A review (Part I). Drugs 1992; 43: 295–315.
Scuderi, P, Wetchler, B, Sung, YF et al. Treatment of postoperative nausea and vomiting after outpatient surgery with the 5-HT3 antagonist ondansetron. Anesthesiology 1993; 78: 15–20.
Pfeiffer, RF, Kang, J, Graber, B, Hofman, R, Wilson, J.Clozapine for psychosis in Parkinson's disease. Mov Disord 1990; 5: 239–42.
Alvir, JM, Lieberman, JA, Safferman, AZ, Schwimmer, JL, Schaaf, JA.Clozapine-induced agranulocytosis: incidence and risk factors in the United States. N Engl J Med 1993; 329: 162–7.
Golden, WE, Lavender, RC, Metzer, WS.Acute postoperative confusion and hallucinations in Parkinson disease. Ann Intern Med 1989; 111: 218–22.
Ropper, AH.Neurological and Neurosurgical Intensive Care. New York, NY: Raven Press; 1993.
Galvez-Jimenez, N, Lang, AE.The perioperative management of Parkinson's disease revisited. Neurol Clin 2004; 22: 367–77.